Karami Hanieh, Aarabi Akram, Hayrabedian Aygineh, Hajhashemi Valiollah
Department of Operating Room Nursing, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran.
Nursing and Midwifery Care Research Center, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran.
Iran J Nurs Midwifery Res. 2024 Jan 9;29(1):60-67. doi: 10.4103/ijnmr.ijnmr_38_23. eCollection 2024 Jan-Feb.
Some studies have reported that mouthwashes can decrease the viral load in the mouth, but there is not much information about the effectiveness of mouthwashes on coronavirus disease 2019 (COVID-19). This study was conducted to compare the impact of using two types of mouthwash, chlorhexidine and sodium bicarbonate, on COVID-19 symptoms and infection.
The present three-group, double-blind clinical trial examined 116 operating room nurses and anesthesia personnel of certain hospitals of Isfahan University of Medical Sciences, Isfahan, Iran. The participants were randomly assigned to three groups: intervention group 1 (chlorhexidine mouthwash), intervention group 2 (sodium bicarbonate mouthwash), and the control group (placebo). Mouthwash was used twice a day (morning and night) for 2 weeks. The participants were monitored in terms of COVID-19-related symptoms for 4 weeks, from the first day of mouthwash use.
Fisher's exact test indicated a significant difference between the chlorhexidine and control groups in terms of the onset of COVID-19-related symptoms ( = 0.02). There was no significant difference in the symptoms of COVID-19 between the groups, but the groups were significantly different in terms of all symptoms at a 4-week interval ( = 0.04). Furthermore, headache was less observed in the chlorhexidine ( = 0.007) and sodium bicarbonate ( = 0.03) groups compared to the control group.
The use of 0.2% chlorhexidine mouthwash can decrease the onset of COVID-19-related symptoms in health-care workers. In addition, this mouthwash can partially reduce the symptoms of this disease in comparison to the control and sodium bicarbonate groups.
一些研究报告称漱口水可降低口腔中的病毒载量，但关于漱口水对2019冠状病毒病（COVID-19）有效性的信息不多。本研究旨在比较使用两种漱口水（洗必泰和碳酸氢钠）对COVID-19症状及感染的影响。
本三项分组双盲临床试验对伊朗伊斯法罕医科大学某些医院的116名手术室护士和麻醉人员进行了研究。参与者被随机分为三组：干预组1（洗必泰漱口水）、干预组2（碳酸氢钠漱口水）和对照组（安慰剂）。漱口水每天使用两次（早晚各一次），持续2周。从使用漱口水的第一天起，对参与者进行为期4周的COVID-19相关症状监测。
费舍尔精确检验表明，洗必泰组与对照组在COVID-19相关症状的发作方面存在显著差异（P = 0.02）。各组之间COVID-19症状无显著差异，但在4周间隔时，各组在所有症状方面存在显著差异（P = 0.04）。此外，与对照组相比，洗必泰组（P = 0.007）和碳酸氢钠组（P = 0.03）头痛症状较少。
使用0.2%洗必泰漱口水可减少医护人员中COVID-19相关症状的发作。此外，与对照组和碳酸氢钠组相比，这种漱口水可部分减轻该疾病的症状。
